Peter L. Hoang, President and CEO of TapImmune, stated, “I am delighted that the U.S. Department of Defense has again chosen to support our technology and therapeutic platform with another funding commitment.
“We remain grateful to the U.S. Department of Defense and Mayo Clinic for enabling TapImmune to gain invaluable clinical safety and efficacy insight for TPIV200 under this grant,” said TapImmune President and CEO Peter Hoang.
…Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials
Jacksonville FL, June 7, 2016 – TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company is pleased to announce that the Company has exercised its option agreement with Mayo Clinic and signed a worldwide license agreement to a proprietary HER2neu vaccine technology.
…Trial will Utilize Folate Receptor Alpha Vaccine Licensed to TapImmune for Commercialization
JACKSONVILLE, Florida, September 15, 2015 /PRNewswire/ –
TapImmune, Inc. (TPIV), congratulates Mayo Clinic for being awarded a grant of $13.3 million from the U.S. Department of Defense. This grant, commencing September 15, 2015, will cover the costs for a 280 patient Phase II Clinical Trial of Folate Receptor Alpha Vaccine in patients with Triple Negative Breast Cancer.